GSK begins Phase lll study in patients with eosinophilic granulomatosis with polyangiitis

GlaxoSmithKline (GSK) has initiated a Phase III trial of an investigational IL-5 antagonist mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news